Effects of alpha-lipoic acid supplementation in gestational diabetes mellitus

Effects of Alpha-lipoic acid supplementation on the Liver and kidney function tests in women with gestational diabetes

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160111025949N6

Enrollment

Registered

2018-01-02

Start date

2017-12-30

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational diabetes mellitus. Gestational diabetes mellitus

Interventions

Intervention 1: Intervention group: One capsule alpha-lipoic acid (100 mg) per day for 8 weeks. Intervention 2: Control group: One capsule placebo cellulose acetate (100 mg) per day for 8 weeks.

Treatment - Drugs

Placebo

Intervention group: One capsule alpha-lipoic acid (100 mg) per day for 8 weeks

Control group: One capsule placebo cellulose acetate (100 mg) per day for 8 weeks

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: No history of gestational diabetes mellitus Not consumption of vitamin and mineral supplements during the last 6 months

Exclusion criteria

Exclusion criteria: Preterm delivery Preeclampsia The need for insulin or oral medication for lowering blood sugar during the intervention Bed rest Alcoholism Smoking

Design outcomes

Primary

Measure	Time frame
Fasting glucose. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Colorimetric.;Fasting insulin. Timepoint: Before and after 8 weeks of intervention. Method of measurement: ELISA.;HbA1C. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Chromatoghraphy.;Gamma-glutamyltransferase. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Colorimetric.;Alanine transaminase. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Colorimetric.;Aspartate transaminase. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Colorimetric.;Alkaline phosphatase. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Colorimetric.;Urea. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Colorimetric.;Creatinine. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Colorimetric.	—

Measure

Time frame

Fasting glucose. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Colorimetric.;Fasting insulin. Timepoint: Before and after 8 weeks of intervention. Method of measurement: ELISA.;HbA1C. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Chromatoghraphy.;Gamma-glutamyltransferase. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Colorimetric.;Alanine transaminase. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Colorimetric.;Aspartate transaminase. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Colorimetric.;Alkaline phosphatase. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Colorimetric.;Urea. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Colorimetric.;Creatinine. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Colorimetric.

—

Secondary

Measure	Time frame
Body mass index. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Formula.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Khosrowbeygi

Arak University of Medical Sciences

a.khosrowbeygi@arakmu.ac.ir+98 86 3417 3645

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026